Tiziana completes Covid-19 study in Brazil
4th Jan 2021 15:19
(Sharecast News) - Biotechnology company Tiziana Life Sciences announced the completion of its clinical study in Brazil on Monday, investigating nasally-administered Foralumab - its proprietary human monoclonal antibody - either alone or in combination with orally administered dexamethasone in Covid-19 patients.
Read moreCourt gives Tiziana capital reduction the nod
29th Oct 2020 16:04
(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Thursday that the capital reduction required for the demerger of StemPrintER Sciences, and to enable the ultimate allotment of Accustem Sciences shares to its shareholders, has been sanctioned by the court.
Read moreTiziana gets US patent for 'TZLS-501' antibody
24th Aug 2020 14:19
(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.
Read moreTiziana inks four deals for development of Covid-19 treatment
4th Aug 2020 11:07
(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.
Read moreTiziana extends ADS sales agreement with ThinkEquity
12th Jun 2020 09:39
(Sharecast News) - Tiziana Life Sciences announced an extension to the current 'at the market sales agreement' with ThinkEquity, a division of Fordham Financial Management, on Friday.
Read moreTiziana Life Sciences files for patent on potential Covid-19 therapy
27th Apr 2020 09:43
(Sharecast News) - Biotechnology company Tiziana Life Sciences has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R), it announced on Monday, as a potential therapy for the management of Covid-19 disease.
Read moreTiziana Life Sciences expediting development of Covid-19 drug
11th Mar 2020 12:15
(Sharecast News) - Tiziana Life Sciences said on Wednesday that it is expediting the development of a drug that could help in the treatment of people infected with Covid-19.
Read moreTiziana initiates study of 'Foralumab' in coated capsule form
4th Dec 2019 15:38
(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.
Read moreFDA asks Tiziana for more information on next 'foralumab' trial
1st May 2019 10:08
(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.
Read moreTiziana completes patient enrolment in ongoing Milciclib study
3rd Dec 2018 14:27
(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that patient enrolment in its ongoing Phase 2a clinical trial, known as CDKO-125A-010, was now completed.
Read moreTiziana seeks trial for multiple sclerosis 'game changer'
16th Aug 2018 11:47
(Sharecast News) - Tiziana Life Sciences on Thursday submitted an application to initiate phase one clinical trials for a new treatment of neurodegenerative diseases to the US food and drug administration.
Read moreTiziana Life Sciences makes breakthrough oral treatment for inflammatory diseases
16th Nov 2016 09:34
(ShareCast News) - Tiziana Life Sciences, the clinical stage biotechnology company, announced that new data has demonstrated the potential of its novel oral therapy with foralumab for non-alcoholic steatohepatitis (NASH), diabetes and other life threatening inflammatory diseases. Oral efficacy in hu
Read moreTiziana Life looks for secrets of long life with new acquisition
18th Jul 2016 12:03
(ShareCast News) - Tiziana Life Sciences has purchased key assets from Sardinia-based biobanking and genomics research company Shardna for €258,000, giving it access to the genetic data of nearly 13,000 people from the Ogliastra region, where life expectancy is high. The AIM-listed clinical stage bi
Read moreTiziana partnership scoops innovation award
1st Jun 2016 14:49
(ShareCast News) - Clinical stage biotechnology company Tiziana Life Sciences was celebrating on Wednesday, after its partnership with researchers at Cardiff University collected a fresh award. The AIM-traded company said the partnership, which has led to the development of a potential new drug for
Read moreTiziana Life Sciences appoints new CFO
4th Apr 2016 07:32
(ShareCast News) - Tiziana Life Sciences has appointed Tiziano Lazzaretti as Chief Financial Officer, effective immediately. Confirming the move on Monday, the AIM-listed biotechnology company said the appointment was not a board level position. Lazzaretti has extensive experience in the healthcare
Read more